NDAOPHTHALMICSOLUTION/DROPS
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
6/8 — Strong
MIEBO (perfluorohexyloctane) by Bausch + Lomb is perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. Approved for dry eye disease. First approved in 2023.
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIEBO (perfluorohexyloctane) is a novel semifluorinated alkane ophthalmic solution approved by the FDA on May 18, 2023, for treatment of signs and symptoms of dry eye disease (DED). The drug works by forming a monolayer at the air-liquid interface of the tear film to reduce tear evaporation, though the exact mechanism in DED is not fully understood. MIEBO represents a new chemical class in the dry eye market and addresses an underserved patient population with a mechanism distinct from traditional aqueous lubricants and anti-inflammatory agents.
$0.0BPart D
11.1 years to LOEMechanism of Action
Perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. The exact mechanism of action for MIEBO in DED is…
Pharmacologic Class:
Semifluorinated Alkane
Indications (1)
Clinical Trials (7)
SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease
Started Feb 2026
260 enrolled
Dry Eye Disease (DED)
A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
Started Dec 2025
0Dry Eye Disease
A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
Started Jul 2025
104 enrolled
Dry Eye
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
Started Jul 2024
216 enrolled
Dry Eye
A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy
Started Apr 2024
97 enrolled
Dry Eye
Worked on MIEBO at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.